WHO Consults On Revised Scheme To Certify Quality Of Pharmaceutical Products
The WHO has proposed a revised certification scheme on the quality of pharmaceutical products to address recent changes in the drug regulation environment, including the rapid globalization of the pharmaceutical manufacturing sector.
You may also be interested in...
New Manufacturing Technologies And Regulatory Convergence Expected To Improve Access In Developing Countries
The key to increasing access to biopharmaceuticals and vaccines in developing countries and to break affordability barriers is through advanced manufacturing platforms and regulatory partnerships such as AVAREF and through WHO's standards setting activities. Yet doubts about the continuing viability of the CPP in promoting access were expressed at recent industry meeting.
A project being run in the Americas will assess the way that the Certificate of a Pharmaceutical Product is used and whether it meets the needs of countries in the region. The move is part of the revision of the World Health Organization’s quality certification scheme.
Changes to an ICH guideline could help drug companies that are being deluged with post-approval safety information to cut down on noisy, low-value data.